Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
65.19
USD
|
-0.58%
|
|
-1.17%
|
+3.81%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,354
|
1,256
|
3,787
|
5,976
|
7,092
|
-
|
-
|
Enterprise Value (EV)
1 |
1,354
|
1,256
|
3,787
|
5,976
|
7,092
|
7,092
|
7,092
|
P/E ratio
|
-8.8
x
|
-12.3
x
|
-13.9
x
|
-15.2
x
|
-16.3
x
|
-15
x
|
-14.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-15.4
x
|
-12.3
x
|
-16.5
x
|
-12.9
x
|
-14.8
x
|
-14.7
x
|
-
|
EV / FCF
|
-
|
-9.81
x
|
-57.1
x
|
-19.1
x
|
-16.8
x
|
-17.9
x
|
-17.8
x
|
FCF Yield
|
-
|
-10.2%
|
-1.75%
|
-5.24%
|
-5.95%
|
-5.59%
|
-5.61%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
50,950
|
52,785
|
78,980
|
95,154
|
108,795
|
-
|
-
|
Reference price
2 |
26.57
|
23.79
|
47.95
|
62.80
|
65.19
|
65.19
|
65.19
|
Announcement Date
|
3/29/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-88.18
|
-101.9
|
-229.7
|
-464.9
|
-480.1
|
-484
|
-
|
EBIT
1 |
-
|
-89.58
|
-103.7
|
-232.3
|
-468
|
-500.9
|
-551.8
|
-604.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-89.22
|
-100.1
|
-223.5
|
-402.3
|
-454.1
|
-521.8
|
-574.1
|
Net income
1 |
-50.27
|
-89.22
|
-100.1
|
-223.5
|
-402.3
|
-451.8
|
-506.7
|
-540.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-13.24
|
-3.020
|
-1.930
|
-3.440
|
-4.140
|
-4.011
|
-4.341
|
-4.424
|
Free Cash Flow
1 |
-
|
-
|
-127.9
|
-66.37
|
-312.9
|
-422
|
-396.3
|
-398.1
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/22/20
|
3/29/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-195.8
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.85
|
-39.22
|
-47.89
|
-58.58
|
-86.57
|
-71.19
|
-87.15
|
-113
|
-196.7
|
-114.5
|
-121.4
|
-128.5
|
-136.5
|
-127
|
-129
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-28.56
|
-38.99
|
-48.53
|
-57.92
|
-78.05
|
-60.46
|
-68.34
|
-92.66
|
-180.8
|
-95.02
|
-108.1
|
-115.8
|
-129.6
|
-127
|
-129
|
Net income
1 |
-28.56
|
-38.99
|
-48.53
|
-57.92
|
-78.05
|
-60.46
|
-68.34
|
-92.66
|
-180.8
|
-95.02
|
-111.5
|
-116.2
|
-129
|
-127
|
-129
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5400
|
-0.6800
|
-0.8000
|
-0.9300
|
-1.020
|
-0.7000
|
-0.7000
|
-0.9100
|
-1.820
|
-0.8500
|
-0.9800
|
-1.016
|
-1.122
|
-1.100
|
-1.150
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/7/22
|
2/27/23
|
5/8/23
|
8/8/23
|
11/6/23
|
2/27/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-128
|
-66.4
|
-313
|
-422
|
-396
|
-398
|
ROE (net income / shareholders' equity)
|
-
|
-44.6%
|
-17.7%
|
-36.1%
|
-36.7%
|
-34.1%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-1.580
|
-2.340
|
-2.630
|
-2.990
|
-3.120
|
-3.090
|
-
|
Capex
1 |
-
|
1.16
|
6.56
|
5.85
|
16.1
|
16.1
|
11.6
|
12.6
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/22/20
|
3/29/21
|
2/28/22
|
2/27/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
65.19
USD Average target price
103.1
USD Spread / Average Target +58.22% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.81% | 7.09B | | +3.91% | 109B | | +10.87% | 105B | | +1.28% | 22.25B | | -13.14% | 22.09B | | -7.05% | 18.68B | | -38.36% | 17.58B | | -10.66% | 16.85B | | +3.75% | 13.76B | | +36.70% | 12.46B |
Bio Therapeutic Drugs
|